Eli Lilly (NYSE:LLY) announced that its Alzheimer’s medication Kisunla (donanemab) has secured a favorable opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). The committee recommended Kisunla for treating early symptomatic Alzheimer’s disease.
Following the CHMP’s endorsement, the European Commission is expected to issue a final regulatory decision on donanemab in the near future.
The positive recommendation was mainly based on findings from two key clinical trials, TRAILBLAZER-ALZ 2 and TRAILBLAZER-ALZ 6, which formed the backbone of the committee’s assessment.
If the European Commission grants approval, Kisunla would become available as a treatment option for early symptomatic Alzheimer’s patients throughout the European Union.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.